Merck, Sanofi, Syngenta & GSK announce full year results for 2014

Pharma giants Merck, Sanofi & GSK announced their full-year results for 2014 this week, as did global AgroChemical multinational Syngenta. Syngenta reported sales of $15.1 billion USD, achieving their integrates

Share
Thermo Fisher Strengthens Bioproduction Offering by Acquiring Advanced Scientifics

Thermo Fisher Scientific have announced their acquisition of ASI (Advanced Scientifics, Inc.) for a cash payment of $300 million USD as the company seeks to strengthen their bioproduction offerings. ASI

Share
23andMe and Genentech Announce Research Partnership

Controversial DNA sequencing company 23andMe announced the first of 10 deals to be signed with large biotech and pharma firms on Tuesday January 6. Their $60 million partnership with Genentech

Share

Illumina Reports Record Financial Results for Third Quarter of Fiscal Year 2014 Illumina, Inc. announced its financial results for the third quarter of 2014. Third quarter 2014 results: Revenue of

Share

QIAGEN demonstrates expanded bioinformatics workflows at ASHG; strong market adoption as researchers analyse genomic data on more than a quarter-million samples in secure private cloud Translational research in cancer and

Share

Roche delivers solid sales growth for the first nine months of 2014 Group sales up 5% at CER1, stable in Swiss francs 4% higher sales in Pharmaceuticals Division, with strong

Share

Company terminates existing sales agreement with BlueWave Healthcare Consultants Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC) technology for clinical diagnostics and scientific discovery, today outlined

Share

Beckman Coulter has received U.S. Food and Drug Administration (FDA) 510(k) clearance on its Power Express high-speed automated sample processing system. Designed to meet the needs of the most demanding

Share

BD To Acquire CareFusion For $12.2 Billion BD and CareFusion announced a definitive agreement under which BD will acquire CareFusion for $58.00 per share in cash and stock, or a

Share

Thermo Fisher Scientific Reports Third Quarter 2014 Results Third Quarter Highlights Grew adjusted earnings per share (EPS) by 32% to $1.71. Increased revenue by 31% to $4.17 billion. Expanded adjusted

Share